Browsing Tag
LOXO-292
5 posts
LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the…
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers
Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug…
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in…
Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm…
Lilly to acquire Loxo Oncology in $8bn deal: A game-changer in precision cancer treatment
Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire…